Recommendation of the President – Breyanzi (lisocabtagene maraleucel)
On 31 July 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 108/2025 on the appraisal of drug Breyanzi (lisocabtagene maraleucel) under the drug program “Treatment of patients with B-cell lymphomas (ICD-10: C82, C83, C85)”